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Abstract: Recombinant human bone morphogenetic protein-2 (rhBMP-2) is an osteoinductive protein approved for use 
in oral and maxillofacial defect reconstruction. Growth factors act as mediators of cellular growth on morphogenesis and 
mythogenesis phases. Utilized as recombinant proteins, these growth factors need the presence of local target cells capable 
of obtaining the required results. This cell population may be present at the wound site or added to scaffolding material 
before implantation at the surgical site.  
The aim of this study is to evaluate the clinical and radiographic results of a reported case with a large bone defect, treated 
with an absorbable collagen sponge, rhBMP-2 and a titanium plate and mesh. The Authors want to report a case which 
shows the resulting effectiveness of the rhBMP2 action regarding a large, mandibular defect reconstruction. This case also 
shows how the removal of a rare tumor such as a ghost cell tumor of the jaw may be treated without harvesting bone from 
another body site. A quick diagnosis of the lesions is important in order to perform the most suitable treatment. The 
Authors also underline the clinical and histological steps to insure the correct treatment is carried out to solve the case.  
Moreover, from results obtained from this case, it is possible to highlight several clinical benefits for the patient by adding 
rhBMP-2 to the common allograft to not only have alveolar reconstruction defects and sinus floor augmentation, but also 
to have alveolar cleft reconstruction and to treat segmental defects.  
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INTRODUCTION 
Recombinant human bone morphogenetic protein-2 
(rhBMP-2) is an osteoinductive growth factor that has the 
potential to greatly reduce the need for autogenous bone 
grafts [1]. Urist demonstrated the capabilities of demineral-
ized bone matrixes to induce ectopic bone formation in a rat 
muscle pouch. He first introduced the concept that growth 
factors can induce bone formation independently of the bone 
tissue condition [2].  
The emergence of rhBMP-2 as a viable alternative to 
common bone grafts is related to two important clinical chal-
lenges. The first is to eliminate the need to harvest bone from 
the iliac crest or other sites when performing oral and maxil-
lofacial reconstruction techniques because of morbidity as-
sociated with these procedures [3]. The second reason is to 
enhance the degree of new bone formation, ultimately lead-
ing to positioning of dental implants, for treating several 
defects of the facial skeleton [4, 5]. 
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Autogenous bone has long been considered the “gold 
standard”. However, there are significant, potential disadvan-
tages. Probably the greatest potential advantage for using 
rhBMP-2 is avoiding the need for graft harvesting thus 
eliminating any morbidity associated with it. Complications 
of harvesting extra oral bone grafts such as the iliac crest 
may occur in as many as 15% to 25% of patients [6-9].  
Problems associated with iliac crest bone harvesting are 
pain and the risk of significant morbidity. Graft harvesting 
complications include increased surgical morbidity from an 
additional operative site, including chronic donor site pain, 
increased operative time, and additional cost. For larger de-
fects, the quantity of bone available for harvest may be in-
sufficient for larger defects or in patients who have under-
gone previous graft harvests. Summary analysis of prospec-
tive studies has shown that rhBMP-2 is superior to an auto-
graft in obtaining lumbar fusion success [10-12]. Although it 
remains to be seen whether this is true for maxillofacial re-
constructions, studies thus far are promising. In studies com-
paring iliac crest bone grafts to rhBMP-2 in cleft palate pa-
tients and patients undergoing a sinus lift procedure, the 
groups who received rhBMP-2 performed as well as the 
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In contrast to the rhBMP-2 application with absorbable 
collagen sponge, transplanted autogenous bone may need to 
be resorbed or remodelled before fusing. rhBMP-2 may ac-
celerate the creeping substitution of an allograft by stimulat-
ing an osteoclastic response with an osteoblastic response. 
BMP has a role in the regulation of bone turnover via cou-
pled osteoblastic and osteclastic activity and BMP mediated 
signals are involved in the osteoclastic resorption [15, 16].  
In 2007, the FDA granted approval of rhBMP-2 (Infuse 
Bone Graft-Medtronic, Memphis TN
®) as an alternative to 
autogenous bone graft sinus augmentation and for localized 
alveolar ridge augmentations for defects associated with ex-
traction sockets. This approval was based on data from 312 
patients enrolled in a total of 5 clinical studies. rhBMP-2 is 
contraindicated for patients with a known hypersensitivity to 
rhBMP-2 or bovine type I collagen. It should not be used in 
the vicinity of a resected tumor, in patients with any active 
malignancy, in infected sites or pregnant woman [17]. 
The use of rhBMP-2 delivered to a surgical site in com-
bination with an absorbable collagen sponge has been inves-
tigated in preclinical and clinical studies of localized alveolar 
grafting as well as sinus floor augmentation prior to im-
plants. A pivotal study indicated that the use of rhBMP-2 
provides clinical and radiographic results equivalent to those 
after the use of autogenous grafting [18]. 
The aim of this work is to investigate the clinical and ra-
diographic long-term results of a hemi-mandibular recon-
struction by using rhBMP2, absorbable collagen sponge and 
titanium mesh. 
CASE REPORT 
An 18 year old patient was undergoing orthodontic 
treatment by a local dentist. During a visit, the dentist re-
corded a consistent swelling in the mandibular left corpus. A 
presumptive diagnosis of vascular malformation was made, 
and the patient was referred to the author for management. A 
panorex investigation showed a large tissue mass and exten-
sion of the lesion, and a more ominous growth was suspected 
(Figs.1, 2, 3).  
A biopsy was taken from the lesion and the histological 
report showed it to be a Dentinogenic Ghost Cell Tumor 
(Fig. 4). The decision was made to manage the local tumor 
with en bloc resection and immediate reconstruction by us-
ing an inferior titanium plate, in order to maintain, without 
alteration, the mandibular soft tissue space. Moreover, 
rhBMP2 and absorbable collagen sponge (ACS) were ap-
plied inside a titanium mesh (Figs. 5-6). The patient was then 
placed into a maxillomandibular fixation (MMF) and an in-
 
Fig. (1). Orthopantomography showed long mandibular circular 
lesion involving several lower jaw teeth.  
 
Fig. (2). A significant swelling in the left mandible may be appreci-
ated before the tumor resection. 
 
Fig. (3). Clinical left mandibular swelling. 
 
Fig. (4). Dentinogenic Ghost Cell Tumor Histological features. 
 
Fig. (5). Anatomic tumor extension after the elevated flap.  
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ferior 2.4-mm locking reconstruction plate (Synthes, Paoli, 
PA) was chosen for the mandibular reconstruction. A full-
thickness incision was made in the mucosa along the defect. 
An advantage of placing the incision more buccally is that 
closure after grafting is much easier. The incision was ex-
tended to the bone. Then, subperiosteal dissection was used 
to adequately expose the entire defect. Broad exposure of the 
underlying ridge is important as it allows better visualization 
of the defect as well as freeing up soft tissue for easier clo-
sure. Important anatomical landmarks (mental nerve) can be 
visualized if deemed necessary in order to avoid damage. 
Once the underlying ridge was exposed, a mesh was coun-
tered to correct the defect. It is important to overcorrect by as 
much as 10-20% as some resorption is expected. Anterior 
defects require a curvature of the mesh in order to rebuild a 
natural curve of the arch. The underlying ridge is pierced 
with a small drill to stimulate bleeding. This accomplishes 
faster integration of the graft as well as supplying additional 
stem cells to the area. rhBMP-2 was then placed on the ab-
sorbable collagen sponge. A portion of the collagen sponge 
was then cut into small 2-3 mm pieces and mixed throughout 
a bone allograft (mineralized or demineralized). Next, the 
rhBMP-2/absorbable collagen sponge/allograft was placed 
into the mesh (Fig. 7). The mesh and graft material were 
then secured in place with a minimum of two screws but 
preferably more. Monocortical screws were used in the area 
of the inferior alveolar nerve in order to avoid nerve damage. 
TC and OPT post op were performed (Figs. 8, 9). The post-
operative course was uneventful with the patient doing very 
well. On examination of the patient at the 3 month follow up, 
clinical palpation of the mucosa overlying the resected area 
showed a hard indurated calcifying surface of the regener-
ated bone. The patient exhibited radiographic evidence of 
bone formation as early as 3 or 4 months post-operatively, 
and mandibular continuity was regained as demonstrated 
both clinically and radiographically (Figs. 10, 11). At the 9 
month follow up, the titanium mesh was removed and dental 
implants were placed in position (Figs. 12, 13).  
DISCUSSION 
Pre-prosthetic augmentation procedures, including alveo-
lar ridge augmentation, using bone grafts are commonplace. 
Jovanovic  et al. performed a histologic study of a canine 
ridge augmentation with BMP [19]. They found no signifi-
cant difference between implants with rhBMP-2 induced 
 
Fig. (10). A 3-4 months clinical evaluation. A good soft tissue heal-
ing can be appreciated. 
 
Fig. (11). No more swelling is underlined at frontal image 6 months 
post op. 
 
Fig. (12). OPT evaluation at 9 month follow up at removing tita-
nium mesh time. Bone regeneration can be appreciated on the left 
body mandible. 
 
Fig. (7). Mandibular reconstruction is performed with low titanium 
plate, rhBMP-2 and ACS covered by a titanium mesh. 
 
Fig. (8). Post op radiographic evaluation.  
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bone compared to resident bone. rhBMP-2 allows installa-
tion, osseointegration, and long term functional loading of 
dental implants. 
According to a study performed by Degidi et al., titanium 
mesh is helpful in maintaining space with large mandibular 
and maxillary defects. Moreover, the use of occlusive mem-
branes (resorbable or non resorbable) may prevent vascular 
in-growth and decrease the available adult stem cells [20].  
The osteoconductivity capabilities of rhBMP-2 have been 
widely studied in different bone healing environments. Pre-
clinical and clinical research has demonstrated that rhBMP-2 
combined with absorbable collagen sponge can induce new 
bone formation. rhBMP-2 has been show to heal critical size 
bone defects in animal models as well as clinical trials [21, 
22]. 
The half-life of rhBMP-2 is only minutes in the blood-
stream; thus, it must be administered locally over a period of 
time to bleeding bone to stimulate bone induction associated 
with new bone formation. The absorbable, collagen sponge 
carrier matrix provides a means of delivering rhBMP-2 to 
the surgical site and retains the growth factor at the site. It 
has a limited ability to prevent soft tissue prolapse into the 
defect thus enabling bony vascular growth to occur during 
rhBMP-2 induced bone formation [23]. The ACS is type I 
collagen derived from highly purified bovine tendon. The 
ACS lacks structural stability and is compressed by the soft 
tissue walls of the defect. Future carriers with more struc-
tural stability will aid in maintaining the space for optimal 
bone formation to occur. The absorbable collagen sponge is 
susceptible to compression from the overlying tissue. This 
compression problem has meant that other ways to maintain 
space should be considered. Options include engineering an 
alternative carrier, addition of compressive resistant osteo-
conductive material, supporting the space with a membrane 
or mesh, or using screws or implants to “tent up” the tissue. 
Combining the rhBMP-2 with a graft extender may improve 
the economic feasibility of rhBMP-2 reducing the required 
protein dose [24]. 
 Both rhBMP-2 and rhBMP-7 have been studied in thou-
sands of patients and tens of thousands of animal with a high 
safety profile [25]. It is estimated that over 500,000 patients 
have been treated with rhBMP-2. Low risk, similar to clini-
cal trials leading to approval, can be expected with “on la-
bel” use. Transient increases in antibodies to BMPs, devel-
oped in 5-10% of patients, does not affect bone healing on 
first exposure but little is known to-date regarding the effects 
of multiple exposures. Carreon et al. studied patients who 
were re-exposed to rhBMP for spine surgery [26]. In the 
ninety-six patients who had at least 2-spine surgeries using 
rhBMP-2, they found no significant difference in the number 
of complications between the first and second surgeries. 
There were no wound problems or allergic reactions among 
the twelve patients who had a third surgery with rhBMP-2. 
They concluded that multiple exposures to rhBMP-2 does 
not increase the risk of wound infections/problems or result 
in clinically detectable allergic reactions. 
When used “off label”, there are possible adverse results 
that must be balanced against the benefit of using rhBMP-2. 
Changing the recommended concentration resulted in incon-
sistent bone formation. If a higher concentration is used, 
local edema or fluid connection may occur as has been re-
ported in some cases of anterior cervical discectomy and 
fusion using BMP instead of autogenous bone [27]. Adverse 
facial edema has also been noted when rhBMP-2 was used 
for cranial reconstruction for craniosynostosis [28]. Because 
BMPs can accelerate bone resorption in addition to bone 
formation, using more resorbable carriers which have not 
been carefully tested with them, may result in accelerated 
resorption of the bone. As with any new technology, con-
cerns over additional costs of such interventions should be 
considered. As discussed by Kuklo et al. there is a compel-
ling argument for the continued use of such technologies, as 
the primary outcome measures of union, rate of infection, 
and reoperation were all improved with rhBMP-2 in a large 
number of patients [29]. 
Despite the extent of bone formation, there has not been 
any evidence of bone formation extending beyond the 
boundaries of the defect. The process of induced bone for-
mation is a controlled response to highly concentrated levels 
of rhBMP-2. This bone inducing protein is normally present 
endogenously in the body and it is likely that normal growth 
regulating genes control the growth process and prevent 
over-growth. 
Even if the use of rhBMP-2 in oral surgery seems to give 
predictable and long term results as shown from the large 
number of animal studies and clinical trials, several ques-
tions are still unanswered such as: 
•  What is the ideal grafting material to combine with 
BMPs to enhance bone formation in a specific defect? 
•  Does the addition of BMPs to autogenous bone   
improve the “gold standard”’ 
•  Will alloplastic, allogenic, or xenogenic graft material 
in combination with rhBMP-2 prove to be superior 
than rhBMP-2/ACS alone? 
•  Are there other cytokines that will enhance the   
activity of BMPs? 
As rhBMP-2 is osteoinductive and allografts are osteo-
conductive, it appears logical to combine the two in an effort 
to enhance the amount and rate of bone formation. Future 
studies will help to shed light on these questions as we con-
tinue to strive to improve our understanding of bone healing. 
CONCLUSION 
The published literature suggests that rhBMP-2 is clini-
cally effective in treatment of critical size defects in both 
 
Fig. (13). 4 dental implants positioned at 9 month follow up after 
tumor resection in order to reconstitute function and aesthetic of the 
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extremities as well as in the maxillofacial region. Moreover, 
the excellent results of this case report seems to support the 
ability of rhBMP-2 to predictably induce new bone forma-
tion at the implantation site. Further study will continue to 
support this conclusion and offer definitive proof that 
rhBMP-2 & ACS can be a safe alternative to the harvesting 
of autograft in maxillofacial reconstruction just as it has been 
in orthopaedic applications. rhBMP-2 repair has significant 
advantages for the patient: large bone defects do not need 
non-oral donor sites or long surgical procedures. In the pre-
sented case, the possibility of using rhBMP-2 significantly 
reduced patient pain and discomfort. 
 Other advantages include shorter stay in hospital, avoid-
ance of gait and sensory disturbance, as well as a decrease in 
possible infection and also the size of the scar formation 
area. Surgical time is reduced since the surgeon does not 
have to harvest autogenous bone from a secondary site.  
In the future, the use of exogenous cytokines, particularly 
those in the BMPs series, will become common and the re-
generation of osseous defects will likely be carried out as a 
clinical outpatient procedure. 
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